Navicixizumab Biosimilar
REQUEST MORE INFO
Catalogue No: abx831373
Price:
US$493.00
(Size: 100 µg)
Orders to United States ship from United States
Add to Cart
Buy It Now
GET A QUOTE
Documents
Datasheet SDS
Navicixizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting DLL4/VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Research Articles on DLL4/VEGFA
| Target | DLL4/VEGFA |
| Research Area | Humanized Monoclonal Antibodies, Biosimilars |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG2 Kappa |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles. |
| Shelf Life | 12 months. |
| Buffer | 0.01 M PBS, pH 7.4. |
| CAS Number | 1638338-43-8 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 5-10 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
